Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.

Biotechnology Research

New Haven, CT 2,979 followers

Clinical-stage biopharmaceutical company

About us

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough. Trevi is headquartered in New Haven, CT.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
New Haven, CT
Type
Privately Held
Founded
2011

Locations

Employees at Trevi Therapeutics, Inc.

Updates

Similar pages

Browse jobs

Funding